目的 探讨通窍耳聋丸联合巴曲酶注射液治疗突发性耳聋的临床疗效。方法 选择2018年7月—2020年12月在郑州大学第一附属医院治疗的102例突发性耳聋患者，根据用药的差别分为对照组和治疗组，每组各51例。对照组静脉滴注巴曲酶注射液，初次10 UB，以后每次5 UB加入150 mL生理盐水。治疗组在对照组基础上口服通窍耳聋丸，6 g/次，2次/d。两组患者均经2周治疗。观察两组患者临床疗效，比较治疗前后两组患者临床症状改善时间及红细胞压积（HCT）、全血黏度（WBV）、纤维蛋白原（FIB）和血浆黏度（PV）水平。结果 经治疗，对照组和治疗组总有效率分别为84.31%、98.04%（P<0.05）。经治疗，治疗组患者症状改善时间明显早于优于对照组（P<0.05）。经治疗，两组HCT、WBV、FIB和PV均明显降低（P<0.05），且治疗组患者指标下降更明显（P<0.05）。结论 通窍耳聋丸联合巴曲酶注射液治疗突发性耳聋患者，不仅可改善临床症状，还可改善血液流变学指标，具有一定临床推广应用价值。

Objective To investigate the clinical effect of Tongqiao Erlong Pills combined with Batroxobin Injection in the treatment of sudden deafness. Methods Patients (102 cases) with sudden deafness in the First Affiliated Hospital of Zhengzhou University from July 2018 to December 2020 were divided into control and treatment groups according to the difference of medication, and each group had 51 cases. Patients in the control group were po administered with Batroxobin Injection, the first dose was 10 UB, then 5 UB Batroxobin Injection was added into 150 mL normal saline. Patients in the treatment group were po administered with Tongqiao Erlong Pills, 6 g/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluation was evaluated, the disappearance time of clinical symptoms, the levels of HCT, WBV, FIB, and PV in two groups before and after treatment were compared. Results After treatment, the effective rates of the control group and the treatment group were 84.31% and 98.04%, respectively (P<0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, HCT, WBV, FIB, and PV in two groups were significantly decreased (P<0.05), and the indexes of patients in the treatment group were decreased more significantly (P<0.05). Conclusion Tongqiao Erlong Pills combined with batroxobin in treatment of sudden deafness can not only improve clinical symptoms, but also improve hemorheological indexes, which has a certain clinical application value.

R987

河南省医学科技攻关计划（联合共建）项目（LHGJ20190317）